SecBot SecBot
DEFM14A ·Filed Jun 10, 2026

AVNS

AVANOS MEDICAL, INC.
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago SEC0001104659-26-072432
Notable filing: DEFM14A
Actionable Insight ▲ Bullish

Traders should note the stock has already converged to near the $25.00 deal price (closed at $25.00 on June 8, 2026), indicating minimal arbitrage spread. The primary risk is deal completion, focus on regulatory approvals from the Required Government Authorities (Belgium, Sweden, Australia, Saudi Arabia, Mexico, Canada) and the HSR waiting period. If the stock trades below $25.00, the spread reflects execution risk rather than valuation uncertainty. Monitor for any competing Superior Proposal triggering the 4-business-day go-shop match period.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$24.98
T+0 close · Jun 10, 2026 · via day close
Latest settled
−0.16%
T+20 · $24.94
Vs SPY
−2.05%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 11 $24.98entry
  2. T+1 · 5mo ago −0.08%α −0.62% · $24.96
  3. T+5 · 5mo ago −0.44%α −0.87% · $24.87
  4. T+20 · 4mo ago −0.16%α −2.05% · $24.94
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Avanos Medical enters a definitive agreement to be acquired by American Industrial Partners (AIP) for $25.00 per share in cash, representing a 72% premium to the last unaffected closing price of $14.53. The all-cash deal values Avanos at approximately $1.17 billion in equity value, with total required funds of ~$1.42 billion including debt repayment and equity award settlements. The board unanimously recommends approval; a special stockholder vote is set for July 22, 2026.

Key Financial Metrics

Deal Value
$1.2B
Premium
72%
Deal Type
merger

Key Facts

  • Merger consideration: $25.00 per share in cash, no stock component or CVR
  • Premium of ~72% based on $14.53 closing price on April 13, 2026 (last pre-announcement trading day)
  • Equity commitment of $1.4 billion from AIP Fund; no financing condition for Parent
  • Total required funds for the deal: ~$1.42 billion including debt repayment and equity award settlements
  • Board of Directors unanimous recommendation FOR the merger proposal
  • Special meeting scheduled for July 22, 2026; record date June 18, 2026
  • J.P. Morgan issued fairness opinion that $25.00 per share is fair from a financial point of view
  • Approval requires majority of outstanding shares; abstentions and failures to vote count as AGAINST
  • Appraisal rights available under DGCL Section 262 for dissenting stockholders
  • Termination fee payable by Avanos: $37.5 million in certain circumstances
  • Closing expected in second half of 2026, subject to regulatory approvals (HSR, multiple foreign jurisdictions) and stockholder vote
  • Directors and executive officers holding ~0.35% of outstanding shares expected to vote in favor

Financial Impact

$25.00 per share in cash, ~72% premium to unaffected price of $14.53, total equity value ~$1.17B based on 46.85M shares outstanding

stock pricepremium

Risk Factors

  • Regulatory delays or failure to obtain Required Regulatory Approvals (multiple foreign jurisdictions)
  • Antitrust challenge in any of the six Required Government Authority countries
  • Stockholder vote failure: abstentions and non-votes count as AGAINST, requiring majority of all outstanding shares
  • Material Adverse Effect clause could allow termination if Avanos business deteriorates significantly
  • Litigation risk: though none filed as of proxy date, deal-related lawsuits are common
  • Termination fee of $37.5M is not large relative to deal value (~3.2%) but could deter competing bidders

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
DEFM14A Filing (Primary)0001104659-26-072432
Document: tm2614353-2_defm14a.htm0001104659-26-072432

Track record

7 reports on AVNS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jul 27, 202616w ago 25-NSE Neutral 5/10 Entry $24.99 No price data
  2. Jul 2, 202619w ago 8-K / DEFA14A Bullish 7/10 Entry $24.93 to $24.94 ▲ +0.04% −0.89% vs SPY
  3. Jun 10, 202622w ago DEFM14A Bullish 8/10 Viewing Entry $24.98 to $24.87 ▼ −0.44% −0.87% vs SPY
  4. May 5, 202627w ago DEFA14A Neutral 5/10 Entry $24.72 to $24.73 ▲ +0.04% −1.09% vs SPY
  5. Apr 23, 202629w ago DEFA14A Bullish 8/10 Entry $24.71 to $24.65 ▼ −0.24% −1.72% vs SPY
  6. Apr 14, 202630w ago DEFA14A Neutral 4/10 Entry $24.63 to $24.64 ▲ +0.04% −1.35% vs SPY
  7. Feb 26, 202637w ago 8-K Neutral 5/10 Entry $14.49 to $13.79 ▼ −4.83% −3.70% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026